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Screening for latent tuberculosis infection (LTBI) among recent tuberculosis (TB) contacts is an 
important component of TB control, particularly in settings with low TB incidence aiming 
towards pre-elimination(1). However, currently available LTBI diagnostics lack sensitivity, and 
have poor predictive value for incident TB(2–8) Consequently, prevention of one incident TB 
case requires treatment of many for LTBI. This is true for both interferon gamma release assays 
(IGRAs) and the tuberculin skin test (TST); a recent evaluation found that QuantiFERON Gold-In-
Tube (QFT-GIT; Qiagen, Hilden, Germany) and T-SPOT.TB (Oxford Immunotec, UK) perform 
similarly to the TST when a BCG-stratified TST cut-off is used(8).
A newer generation QuantiFERON (QuantiFERON-TB Gold Plus; QFT-Plus) was recently 
launched, adding a second TB antigen tube (TB2) that incorporates short peptides designed to 
stimulate a CD8+ T-cell response, in addition to the CD4+-response tube (TB1) included in 
previous versions. The proposed rationale for this is that CD8+-responses have been associated 
with mycobacterial load and recent TB exposure(9, 10). Initial independent evaluations have 
suggested QFT-Plus may have improved test sensitivity in active TB compared to QFT-GIT(11), 
and that the CD8+-targeted antigen tube response may be associated with proxy measures of 
degree of TB exposure among contacts(12). However, no studies have examined the prognostic 
value of QFT-Plus for predicting incident TB. We aimed to address this key knowledge gap in a 
prospective cohort of UK TB contacts. 
Methods
We recruited adult (≥16 years) contacts of pulmonary and extrapulmonary TB index cases from 
ten London TB clinics, when attending for routine contact screening (07/07/2015-22/11/2016). 
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Participants completed a questionnaire and had blood sampling for QFT-Plus (at least six weeks 
from last known TB exposure). Contacts with evidence of prevalent TB disease (defined as TB 
diagnosed within 21 days of enrolment as per previous work(8)), and those accepting 
preventative therapy (offered in accordance with contemporary national guidance(13, 14)) 
were excluded from analysis. 
Participants were linked to national TB surveillance records held by Public Health 
England, including all statutory TB notifications, to identify those notified with TB (until 
31/12/2017). Notified TB cases were validated by local record review and included culture-
confirmed TB or clinically diagnosed with radiological or histological evidence of TB, where a 
clinician had prescribed treatment with a full course of anti-TB treatment. 
QFT-Plus results were interpreted as per manufacturer guidance, with TB antigen 
responses calculated as TB antigen interferon-γ minus unstimulated control interferon-γ. We 
calculated incidence rates and rate ratios relative to the negative test category, along with 
sensitivity, specificity and predictive values, including the full duration of follow-up.
To assess the incremental value of adding the CD8+-stimulating tube in predicting 
incident TB cases, we compared receiver operating characteristic (ROC) curves and areas under 
the curves (AUCs) when using TB1 only, TB2 only, and the maximal TB antigen tube (higher of 
TB1 and TB2). We also plotted a ROC curve for the calculated difference between the TB1 and 
TB2 tubes (TB2-TB1) as a surrogate for the CD8+-specific response, since it has been 
hypothesised that this may identify contacts with recently acquired M. tuberculosis infection, 
who are at highest risk of TB disease(12). 
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Results
A total of 623 contacts were recruited, of whom 532 (85.4%) had QFT-Plus results (89 missing; 2 
indeterminate) and were followed-up for a median 1.93 years (interquartile range (IQR) 1.65-
2.21). QFT-Plus results were positive in 180/532 (33.8%) (Table 1), of whom 39 (21.7%) 
commenced preventative therapy. One patient was notified with prevalent TB (3 days after 
recruitment). A total of 492 participants were therefore included in the analysis. Baseline 
characteristics were similar between included and excluded participants, except for those who 
commenced preventative therapy being younger than those who did not (Table 1). 
Ten incident TB cases were notified during follow-up (median 222 days after 
recruitment; range 90-688). Of these, median age was 27 (IQR 21-33), 3/10 (30%) were female, 
the majority (7/10; 70%) were of black African or South Asian ethnicity and all were non-UK 
born. All ten cases completed at least six months of TB therapy. A total of 2/10 cases (20.0%) 
were pulmonary in site (both were culture-confirmed), and eight exclusively extra-pulmonary 
(of which 2/8 were culture-confirmed). One participant with TB was diabetic; the remaining TB 
cases were not immunocompromised, and none were HIV-infected. TB incidence rates (per 
1,000 person-years) were 30.6 (95% CI 15.3-61.1) and 3.0 (0.8-12.1) in the QFT-Plus positive 
and negative groups, respectively (incidence rate ratio (IRR) 10.1 (2.2-47.7)). QFT-Plus 
sensitivity for incident TB was 80.0% (44.4-97.5). The positive and negative predictive values 
(PPV/NPV) were 5.7% (2.5-10.9) and 99.4% (98.0-99.9), respectively. Characteristics of QFT-Plus 
for predicting microbiologically-confirmed TB cases are reported in Table 2. 
ROC curves for prediction of incident TB during all follow-up were similar for the TB1, 
TB2 and maximal TB antigen responses (AUCs 0.80-0.82; Figure 1a). TB2 minus TB1, however, 
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did not discriminate TB progressors from non-progressors (AUC 0.44 (95% CI 0.20-0.68)). There 
was very strong correlation between the TB1 and TB2 interferon-γ responses (r = 0.993; p < 
0.001; Figure 1b). 
Discussion
We found that QFT-Plus performance appeared comparable to published evaluations of QFT-
GIT and T-SPOT.TB, with an IRR of 10.1, 80% sensitivity for detection of incident TB, and an 
overall PPV for incident TB of 5.7%(8). Interferon-γ responses in the TB1 and TB2 tubes were 
strongly correlated, and ROC curves showed minimal difference between them for predicting 
incident TB. As a result, the calculated difference between TB1 and TB2 responses, as a proxy 
for the CD8-specific response, did not predict incident TB. However, despite our sample size of 
492 recent TB contacts, the number of TB progressors was small, reflecting low progression risk 
even among contacts. Thus, a larger-scale study is indicated to investigate subtle differences in 
the relative prognostic contributions of the TB1 and TB2 antigen tubes. 
This is the first evaluation of the prognostic value of QFT-Plus test. The prospective 
design allowed the collection of detailed clinical, demographic and laboratory data. Participants 
were recruited while attending routine contact-tracing services, ensuring the study population 
was representative of TB contacts. Our findings are therefore likely generalizable to other low 
incidence settings globally. Moreover, follow-up was robust through linkage to national 
surveillance records using a validated matching algorithm(15), minimising risk of missing 
incident TB cases. 
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A limitation was that the provision of preventative therapy to a subset of the QFT-Plus 
positive patients could have led to selection bias. However, while the subgroup who received 
preventative therapy were younger than those who did not (reflecting national policy at the 
time of the study(13, 14)), other characteristics were similar, suggesting the impact of this bias 
was likely small. Secondly, the TB contacts included both pulmonary and extra-pulmonary index 
cases, reflecting national contact screening policy during the study period(13). PPV of QFT-Plus 
may be higher among populations including only pulmonary TB contacts, due to higher pre-test 
probability of incident TB. However, previous evaluations of the QFT-GIT and T-SPOT.TB have 
also included extra-pulmonary contacts, which allows the current study findings to be put into 
this context(8). Thirdly, serial testing (before and after exposure) was not performed, meaning 
that we are unable to assess QFT-Plus conversions over time, which may provide a more 
reliable measure of recent M. tuberculosis infection. This reflects the reality of contact 
screening practices; the ability of assays to accurately stratify TB risk from a single baseline test 
is therefore a key attribute. The absence of serial testing also means that participants who 
developed incident TB may have been re-exposed to M. tuberculosis during the interval 
between testing and disease, though the overall risk of exposure in the UK (a low TB incidence 
setting) is likely small. Fourthly, QFT-Plus results were missing or indeterminate for 91/623 
patients (14.6%), in keeping with the proportion of missing results for other IGRAs in our recent 
evaluation(8). However, these patients’ characteristics were similar to the overall study 
population, suggesting that risk of subsequent selection bias was likely small. Finally, we 
included both microbiologically-confirmed and clinically-diagnosed TB cases in our outcome 
definition, in keeping with previous IGRA evaluations(3–8). The rationale for this is that extra-
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pulmonary TB, which occurs frequently among TB cases occurring in foreign-born people living 
in the UK(16), is often challenging to prove microbiologically. However, all TB cases diagnosed 
during the study received a full course of TB therapy, and none were de-notified. It is therefore 
likely that these represented true TB cases, with low risk of outcome misclassification. 
In summary, in this first evaluation of the predictive value of QFT-Plus for incident TB, 
performance was comparable to other commercial IGRAs. Better biomarkers are required to 
transform management of TB contacts.
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Table 1: Baseline characteristics of study cohort, stratified by Quantiferon-TB Gold Plus (QFT-
Plus) results and provision of preventative therapy (PT). Data presented as n(%), unless stated 
otherwise. IQR = interquartile range. 
QFT Plus -# QFT Plus + QFT Plus 
missing*
All
No PT# PT  
Age
Median (IQR) 31 (25-43) 43 (32-54) 30 (26-35) 31.5 (23.7-49) 33 (25-46)
Missing 3 (0.9) 2 (1.4) 0 (0) 1 (1.1) 6 (1)
Gender
Male 165 (46.9) 76 (53.9) 24 (61.5) 37 (40.7) 302 (48.5)
Female 180 (51.1) 62 (44) 15 (38.5) 51 (56) 308 (49.4)
Missing 7 (2) 3 (2.1) 0 (0) 3 (3.3) 13 (2.1)
Ethnicity
White 95 (27) 27 (19.1) 9 (23.1) 31 (34.1) 162 (26)
South Asian 117 (33.2) 55 (39) 13 (33.3) 33 (36.3) 218 (35)
Black African or 
Caribbean
67 (19) 30 (21.3) 7 (17.9) 15 (16.5) 119 (19.1)
Other 63 (17.9) 24 (17) 10 (25.6) 9 (9.9) 106 (17)
Missing 10 (2.8) 5 (3.5) 0 (0) 3 (3.3) 18 (2.9)
UK born
No 235 (66.8) 126 (89.4) 33 (84.6) 66 (72.5) 460 (73.8)
Yes 111 (31.5) 11 (7.8) 6 (15.4) 24 (26.4) 152 (24.4)
Missing 6 (1.7) 4 (2.8) 0 (0) 1 (1.1) 11 (1.8)
Contact type
Household 210 (59.7) 96 (68.1) 30 (76.9) 49 (53.8) 385 (61.8)
Family non-
household
19 (5.4) 7 (5) 2 (5.1) 3 (3.3) 31 (5)
Work or Social 62 (17.6) 19 (13.5) 4 (10.3) 14 (15.4) 99 (15.9)
Other 13 (3.7) 3 (2.1) 2 (5.1) 2 (2.2) 20 (3.2)
Missing 48 (13.6) 16 (11.3) 1 (2.6) 23 (25.3) 88 (14.1)
Diabetes
No 318 (90.3) 120 (85.1) 38 (97.4) 83 (91.2) 559 (89.7)
Yes 20 (5.7) 18 (12.8) 0 (0) 6 (6.6) 44 (7.1)
Missing 14 (4) 3 (2.1) 1 (2.6) 2 (2.2) 20 (3.2)
HIV
No 331 (94) 137 (97.2) 37 (94.9) 84 (92.3) 589 (94.5)
Yes 4 (1.1) 0 (0) 1 (2.6) 2 (2.2) 7 (1.1)
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Missing 17 (4.8) 4 (2.8) 1 (2.6) 5 (5.5) 27 (4.3)
Follow-up (years)










Total 352 141 39 91 623
*Includes 2 patients with indeterminate QFT-Plus results.
#Included in primary analysis
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Table 2: Incidence rates, rate ratios, and predictive values for incident tuberculosis (TB) during 
follow-up, stratified by Quantiferon-TB Gold Plus (QFT-Plus) result. Data presented as point 
estimates (95% confidence interval). 
QFT Plus + QFT Plus -
TB cases (microbiologically 









Incidence rate ratio 10.1 (2.2-47.7)
Positive predictive value 5.7 (2.5-10.9)
Negative predictive value 99.4 (98-99.9)
Sensitivity 80.0 (44.4-97.5)
Specificity 72.6 (68.4-76.5)
TB cases (microbiologically 
confirmed only) 3 1




Incidence rate ratio 7.6 (0.8-73.1)
Positive predictive value 2.1 (0.4-6.1)
Negative predictive value 99.7 (98.4-100)
Sensitivity 75.0 (19.4-99.4)
Specificity 71.9 (67.7-75.9)
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Figure Legend:
Figure 1: (a) Receiver operating characteristic curves showing performance of QuantiFERON-TB 
Gold Plus for predicting incident tuberculosis during the duration of follow-up, stratified by 
antigen tube interferon-γ responses. TB max = higher of TB1 and TB2; AUC = area under the 
curve (95% confidence interval). (b) Scatterplot showing association of interferon-γ responses 
in the TB1 and TB2 tubes. 
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TB max; AUC=0.81 (0.69-0.93)
TB2 minus TB1; AUC=0.44 (0.20-0.68)
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